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OBJECTIVES: To estimate the costs associated with juvenile idiopathic arthritis
(JIA) for Russia in 2009. METHODS: We used the standard cost of illness (COI)
method adopting the viewpoint of the payers (national and regional governments).
The data was obtained from the national statistics, registries, expert panel inter-
views and literature. The costs were calculated for the total population of JIA pa-
tients in Russia in 2009. We calculated direct medical costs (based on national
reimbursement rates and regional data on drug costs), non-medical costs (social
benefits expenditures) and indirect costs –productivity loss due to the necessity of
providing care for patients by parents. Indirect costs were assessed using friction
costs method. RESULTS: The total costs of JIA in Russia in 2009 was 1.175 billion
RUR (€28,48 mln), or 76,013 RUR (€1843) per patient per year. The highest per person
costs were attributed to patients with systemic JIA – 189,489 RUR (€4594), the
lowest - with oligoarticular type of JIA (40,223 RUR (€975)).The costs for handi-
capped child were 3.9 times higher than for those without disability, mostly be-
cause of different social benefits. The direct medical costs accounted for 31,5% of
total spending, direct non-medical costs – for 55,6%, and indirect costs – for 12,8%.
The share of direct non-medical costs in the overall spending was lower in less
severe patients: 58.3% for the systemic JIA, 57.7% for the polyarticular and 46.4% for
the oligoarticular type of JIA. Direct nonmedical costs represented 75.8% of total
costs for handicapped child versus 42.8% in patient without such status.
CONCLUSIONS: JIA represents significant social and economic burden for the state.
The costs for handicapped child are several times higher than for the one without
disability due to social benefits payments.
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BIOLOGICAL DRUGS- A SWEDISH NATIONAL REGISTER STUDY FOR 1990-2010
Kalkan A, Husberg M, Hallert E, Bernfort L, Carlsson P
Institution of medicine and health, Linköping University, Linköping, Sweden
OBJECTIVES: To study the total socioeconomic impact of rheumatoid arthritis (RA)
in Sweden 1990-2010 and to discuss the changes in costs during this period. The
period is deliberately chosen to cover 10 years before and 10 years after the intro-
duction of biological drugs, TNF-alfa inhibitors. METHODS: A prevalence based
cost of illness study based on data from official statistics. RESULTS: The total
socioeconomic cost of RA was 4.3 billion Swedish SEK (SEK) in 1990, adjusted to the
price level of 2010. This cost was raised to 5.8 billion SEK in 2010. The increase was
mainly due to augmented direct costs for pharmaceuticals. During these 20 years,
the drug costs increase from 10.4 percent of direct costs, to 75 percent of direct
costs in 2010. Of the total costs, drug costs increase from representing 3 to 32
percent. Consequently, the amount of costs that is taken up by indirect costs for RA
is lowered from 75 percent in 1990 to 58 percent in 2010. A decline is also seen in the
amount of costs that are taken up by costs for care for RA patients. CONCLUSIONS:
The relation between direct and indirect costs for RA has changed dramatically
during the last 20 years with an all rising direct cost for pharmaceuticals. There is
a decrease in indirect costs and costs for care which however does not offset the
increase in costs for pharmaceuticals.
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OBJECTIVES: A cost of illness study (COI) evaluates the direct, indirect and intan-
gible costs of a given disease in monetary terms. Depending on perspective, it
consists of different elements, and it values identical cost contents in different
ways. The social perspective takes account of all cost factors from the point of view.
The trends of previous years in Hungary increase the value of COI studies of soci-
etal perspective in the health care-related decision-making process. Several meth-
ods are available for the evaluation of the chronic diseases’ total costs in socially-
oriented COI studies. In this analysis, our aim is – through the example of the
chronic disease rheumatoid arthritis – to present and compare the results of dif-
ferent COI studies from different data resources, furthermore, to identify the ap-
plicability and limits of these studies through the example of rheumatoid arthritis
(RA). METHODS: The value and ratio of indirect cost of RA in Hungary was esti-
mated in three different approaches: 1. International and national published data
from comprehensive review was analyzed in same structure. 2. From ‘Top down’
estimation’s approach the indirect costs of RA was defined from public macro data.
3. From ‘Botton up’ estimation’s approach the indirect costs of RA was defined from
survey with questionnaire among RA patients. RESULTS: The comparison of the
listed resources alongside identical dimensions indicates that the tendencies are
similar although there are significant differences in the order of magnitude.
CONCLUSIONS: Decisions about health care resource allocations affect social wel-
fare. In reimbursement decisions the Hungarian National Health Insurance Fund
(NHIF) uses the payor’s perspective, but in the ranking and evaluation of health
technologies and therapies the societal perspective represents the basis for opti-
mization. COI studies can help in the identification of decision-making focal points,
although this necessitates the assessment and standardization of the applicable
methodologies.
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OBJECTIVES: To describe indirect resource utilization for inpatient ankylosing
spondylitis (AS) patients treated in tertiary public health facilities over a 1-year
period in Turkey, and demographic factors and disease activity scores associated
with indirect costs. METHODS: Medical records of 650 prevalent AS patients at-
tending seven centers at tertiary health care institutions nationwide were exam-
ined to assess annual indirect health care costs. Eligible patients were age18 and
diagnosed with AS for at least 12 months. We assessed relevant indirect cost-
related variables and activities, and actual costs. Multivariate regression was used
to determine the effects of demographic factors on indirect costs. The Pearson
correlation matrix and the association between disease activity scores and indirect
costs were assessed. RESULTS: Average AS patient age was 40.1 11.33 standard
deviation (SD) years and 35% of patients were female. 55% were employees, of
which 59% had employer permission to miss work (average 17 days annually) due
to AS, costing patients an average €412 annually due to workday loss as calculated
based on income level. 2% of patients had other AS-related consultations not cov-
ered by insurance (acupuncture, homeopathic, other), bringing their average an-
nual burden to a2,482. 10.46% of AS patients incurred additional AS-related costs
(e.g. need for new car, apartment, special equipment), spending an additional
a1,978 per year. 6.92% of patients required caregivers, costing €546 annually. Mul-
tivariate regression showed that age and gender played no significant role related
to the increase in indirect costs. Patients needing AS related equipments reported
significantly higher Global Disease Activity (GDA), visual analog scale (VAS), Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI) and lower EuroQoL health
status (EQ-5D) scores. CONCLUSIONS: AS represents a considerable economic bur-
den to Turkey. Studies assessing chronic disease costs, especially in developing
nations, are important to determine efficient allocation of the limited resources in
such regions.
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OBJECTIVES: To estimate risk-adjusted health care costs and identify associated
risk factors for rheumatoid arthritis (RA) expenditures in Turkey using real-world
data. METHODS: This study used research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Incident cases of adult RA
patients with two RA visits at least 60 days apart, identified between June 1, 2010
and December 31, 2010, were required to have no RA diagnosis before June 1, 2010,
with at least 1 year of continuous enrollment forthe baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
theselected patients. RESULTS:Among 693 patients (mean age: 52.08; female: 80%),
19.6% were age 18-39, 60.9% were 40-64 years and 19.5% were age 65 or older. RA
diagnosis was most prevalent in the Marmara region (44%), followed by Central
Anatolia (23%), Aegean (16%), and Mediterranean (11%). Nearly 35%of RA patients
had at least one cardiovascular, diabetic, respiratory or allergy comorbid condition
prior to diagnosis. Most patients were prescribed non-COX inhibitors (79%) and
immunosuppressants (43%), and 4% of patients were prescribed disease-modifying
anti-rheumatic drugs (DMARDs). The total annual cost (a2,000) was comprised of
mainly pharmacy (a1,201), followed by outpatient (a411), and inpatient costs
(a361),and an average copay of a27. Prior comorbid conditions including diabetes,
respiratory disease as well as hospitalization, glucocorticoid and DMARD use sig-
nificantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of RA patients are significantly lower in Turkey rel-
ative to other countries in Europe, yet, pharmaceutical expenditures cover a sig-
nificant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for RA treatment.
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OBJECTIVES: Estimate risk-adjusted health care costs and identify associated risk
factors for rheumatoid arthritis (RA) expenditures in Turkey using real-world data.
METHODS: This study analyzed research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Adult prevalent RA patients
with two RA visits at least 60 days apart, identified between June 1, 2010 and
December 31, 2010, were required to have an RA diagnosis before June 1, 2010, with
at least 1 year of continuous enrollment for the baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
the selected patients. RESULTS: Among 1,920 patients (mean age: 53.91; female:
84%), 13.8% were age 18-39, 66.5% were 40-64 years and 19.7% were age 65 or older.
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